Good news on Trelegy Ellipta keeps on coming

UK pharma major GlaxoSmithKline (LSE: GSK) and its US partner Innoviva (Nasdaq: INVA) have posted positive headline results from the Phase III IMPACT study of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol).

The treatment reduced exacerbations in chronic obstructive pulmonary disorder, compared with the dual therapies Anoro Ellipta (umeclidinium and vilanterol inhalation powder) and Relvar/Breo Ellipta (fluticasone furoate and vilanterol inhalation powder), according to data presented in the week that it became the USA’s first approved once-daily single inhaler triple therapy comprising an inhaled corticosteroid, long-acting muscarinic antagonist and long-acting beta agonist.